The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 63-73

  Malkowicz, S Bruce ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; TUMOR MARKER;

ANTIGEN DETECTION; BLADDER CANCER; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; ENZYME IMMUNOASSAY; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVIEW;

EID: 0033950073     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70235-4     Document Type: Article

References (40)

1. I. Abbate A. D'Introno G. Cardo Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer Anticancer Res 18 1998 3803
2. B.A. Blumenstein W.J. Ellis L.M. Ishak The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence J Urol 161 1999 57
3. M.J. Campbell D. Machin Probability and decision making Medical Statistics—A Commonsense Approach 1996 John Wiley & Sons Chichester, New York 32
4. M.A. D'Hallewin L. Baert Initial evaluation of the bladder tumor antigen test in superficial bladder cancer J Urol 155 1996 2041
5. W.J. Ellis B.A. Blumenstein L.M. Ishak Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors Urology 50 1997 882
6. D.L. Enfield L.M. Ishak W.A. Redmond Hematuria and complement factor H-related protein levels in urine appear to be independent J Urol 159 suppl 1998 243
7. C. Estaller W. Schwaeble M. Dierich Human complement factor H: Two factor H proteins are derived from alternatively spliced transcripts Eur J Immunol 21 1991 799
8. M. Gail Evaluating serial cancer marker studies in patients at risk of recurrent disease Biometrics 37 1981 67
9. R. Heicappel I.C. Wetting M. Schostak Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder Eur Urol 35 1999 81
10. J. Irani F. Desgrandchamps C. Millet BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder Eur Urol 35 1999 89
11. L. Ishak W.J. Ellis A comparison of the BTA stat and the BRA TRAK assays: Two new tests for the detection of recurrent bladder cancer (BC) in urine J Urol 159 suppl 1998 245
12. G. Jarvis J. Li J. Hakulinen Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer Int J Cancer 71 1997 1049
13. B. Johnston A. Morales L. Emerson Rapid detection of bladder cancer: A comparative study of point of care tests J Urol 158 1997 2098
14. R. Kinders T. Jones R. Root Complement factor H or a related protein is a marker for transitional cell cancer of the bladder Clin Can Res 4 1998 2511
15. J. Landman Y. Chang E. Kavaler Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer Urology 52 1998 398
16. H. Leyh R. Hall E. Mazeman Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder Urology 50 1997 49
17. H. Leyh M. Marberger P. Conort Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer Eur Urol 35 1999 52
18. C. Lockhart C. Parent M. Desaulniers Evaluation of a monoclonal antibody test for the detection of superficial bladder cancer Immunocyt J Urol 159 part 2 1998 1876
19. V.B. Lokeshwar C. Obek M.S. Soloway Tumor associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer Cancer Res 57 1997 773
20. C.E. Metz Basic principles of ROC analysis Semin Nucl Med 8 1978 283
21. N. Miyanaga H. Akaza S. Kameyama Significance of the BTA test in bladder cancer: A multicenter trial. BTA Study Group Japan Int J Urol 4 1997 557
22. J.E. Montie S.E. Meyers Defining the ideal tumor marker for prostate cancer Urol Clin North Am 24 1997 247
23. W.M. Murphy I. Rivera-Ramirez C.A. Medina The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms J Urol 158 1997 2102
24. D. Pode A. Shapiro A. Wald Noninvasive detection of bladder cancer with the BTA stat test J Urol 161 1999 443
25. M.P. Raitanen T. Marttila L.J. Teuvo The Bard BTA stat test in monitoring of bladder cancer J Urol 159 1998 244
26. S. Ramakumar J. Bhuiyan J.A. Besse Comparison of screening methods in the detection of bladder cancer J Urol 161 1999 388
27. M.F. Sarosdy R.W. de Vere White M.S. Soloway Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer J Urol 154 1995 379
28. M.F. Sarosdy M.A. Hudson W.J. Ellis Improved detection of recurrent bladder cancer using the Bard BTA stat test Urology 50 1997 349
29. D.H. Schamhart T.M. deReijke H.G. van der Poel The Bard BTA test: Its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer Eur Urol 34 1998 99
30. K. Schmetter D. Habicht D.L. Lamm Multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer J Urol 158 1997 801
31. S. Schneeweiss M. Kriegmair H. Stepp Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent J Urol 161 1999 1116
32. S. Sharma C.D. Zippe L. Pandrangi Exclusion criteria enhance the specificity and positive predictive value of NMP22* and BTA stat J Urol 162 1999 53
33. R.J. Simes M. Zelen Exploratory data analysis and the use of the hazard function for interpreting survival data: An investigator's primer J Clin Oncol 3 1985 1418
34. C. Skerka C. Timman R.D. Horstmann Two additional human serum proteins structurally related to complement factor H J Immunol 148 1992 331
35. M.S. Soloway Editorial—Do we have a prostate specific antigen for bladder cancer? J Urol 16 1999 447
36. M.S. Soloway J.V. Briggman G.A. Carpinito Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment J Urol 156 1996 363
37. L. Thomas H. Leyh Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer Clin Chem 45 1999 472
38. UK/Eire BTA Group The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer: The United Kingdom and Eire Bladder Tumour Antigen Study Group Br J Urol 79 1997 362
39. H.G. Van der Poel M.R. Van Balken D.H. Schamhart Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer Urology 51 1998 44
40. H.G. Weiner C.H. Mian A. Haitel Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer J Urol 159 1998 1876